PURPOSE: To evaluate the relative impact of best and worst eye on vision-related quality of life in patients suffering from age-related macular degeneration (AMD). DESIGN:Quality of life and visual acuity data were collected at baseline during a randomized clinical trial. SETTING: Multicenter (11 centers), international study. PATIENTS: One hundred fourteen patients with a diagnosis of exudative AMD and primary or recurrent subfoveal neovascular membrane (greatest linear dimension of lesion < or =5400 microm; > or =50% of the total lesion was choroidal neovascularization (CNV); classic component of the total CNV > or = 1.0 mm(2)). All patients were over age 50 years, of any race, either sex. INTERVENTION OR OBSERVATION PROCEDURE: NEI-VFQ-39 questionnaire administered to patients at home by trained telephone interviewers. MAIN OUTCOME MEASURES: ETDRS visual acuity (VA) was measured in both eyes separately. Vision-related quality of life (QoL) was assessed using the NEI-VFQ-39. An analysis of variance was performed on the NEI-VFQ scores, including best eye VA (VA > 20/40 vs VA < or = 20/40), worst eye VA (VA > 20/200 vs VA < or = 20/200), and the interaction between the two as independent variables. RESULTS: Best eye VA was 0.34 on average, with VA > 20/40 in 43.0% of patients. Worst eye VA was 0.85 on average, with VA > 20/200 in 32.5% of patients. VA was not linked to general health and ocular pain scores. General Vision, Near Activities, Distance Vision, Driving, Mental Health, Role Difficulties, Dependency, Peripheral Vision, and the Global NEI-VFQ scores were affected by both best eye VA and worst eye VA. CONCLUSION: In the study sample, worst eye VA (< or =20/200) and best eye VA (< or =20/40) contributed independently to vision-related QoL. These results suggest that preserving a minimal visual acuity in the worst eye may contribute to vision-related quality of life.
RCT Entities:
PURPOSE: To evaluate the relative impact of best and worst eye on vision-related quality of life in patients suffering from age-related macular degeneration (AMD). DESIGN: Quality of life and visual acuity data were collected at baseline during a randomized clinical trial. SETTING: Multicenter (11 centers), international study. PATIENTS: One hundred fourteen patients with a diagnosis of exudative AMD and primary or recurrent subfoveal neovascular membrane (greatest linear dimension of lesion < or =5400 microm; > or =50% of the total lesion was choroidal neovascularization (CNV); classic component of the total CNV > or = 1.0 mm(2)). All patients were over age 50 years, of any race, either sex. INTERVENTION OR OBSERVATION PROCEDURE: NEI-VFQ-39 questionnaire administered to patients at home by trained telephone interviewers. MAIN OUTCOME MEASURES: ETDRS visual acuity (VA) was measured in both eyes separately. Vision-related quality of life (QoL) was assessed using the NEI-VFQ-39. An analysis of variance was performed on the NEI-VFQ scores, including best eye VA (VA > 20/40 vs VA < or = 20/40), worst eye VA (VA > 20/200 vs VA < or = 20/200), and the interaction between the two as independent variables. RESULTS: Best eye VA was 0.34 on average, with VA > 20/40 in 43.0% of patients. Worst eye VA was 0.85 on average, with VA > 20/200 in 32.5% of patients. VA was not linked to general health and ocular pain scores. General Vision, Near Activities, Distance Vision, Driving, Mental Health, Role Difficulties, Dependency, Peripheral Vision, and the Global NEI-VFQ scores were affected by both best eye VA and worst eye VA. CONCLUSION: In the study sample, worst eye VA (< or =20/200) and best eye VA (< or =20/40) contributed independently to vision-related QoL. These results suggest that preserving a minimal visual acuity in the worst eye may contribute to vision-related quality of life.
Authors: Christoph Hirneiss; Aljoscha S Neubauer; Carolin A Gass; Ingrid W Reiniger; Siegfried G Priglinger; Anselm Kampik; Christos Haritoglou Journal: Br J Ophthalmol Date: 2006-10-31 Impact factor: 4.638
Authors: Gary C Brown; Melissa M Brown; Sanjay Sharma; Joshua D Stein; Zachary Roth; Joseph Campanella; George R Beauchamp Journal: Trans Am Ophthalmol Soc Date: 2005
Authors: J Jason McAnany; Mohamed A Genead; Saloni Walia; Arlene V Drack; Edwin M Stone; Robert K Koenekoop; Elias I Traboulsi; Alison Smith; Richard G Weleber; Samuel G Jacobson; Gerald A Fishman Journal: JAMA Ophthalmol Date: 2013-02 Impact factor: 7.389